Physician profile
Daniel P Gardner
NPI 1275913279
$12,823.04
in general payments reported to CMS, 2019-2025
35 companies · $3,472 in 2025
The $3,472 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,159 · 2022: $2,240 · 2023: $2,260 · 2024: $2,692 · 2025: $3,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,339 · Education: $85.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,338.70 |
| Education | $85.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,274.08 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,523.92 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,400.64 | 2021-2025 | Cuvitru, Hyqvia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $1,398.41 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,022.93 | 2021-2025 | |
| Genentech USA, INC. | $930.58 | 2021-2025 | Xolair |
| Csl Behring | $709.52 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Amgen INC. | $375.17 | 2021-2025 | Tezspire, Tavneos |
| Grifols USA, LLC | $268.88 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $267.52 | 2021-2024 | |
| Incyte Corporation | $239.73 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $231.07 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.16 | 2021-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Pfizer INC. | $211.54 | 2021-2025 | |
| Kaleo, INC. | $189.57 | 2021-2024 | Auvi-Q |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $188.30 | 2021-2025 | Orladeyo |
| Verona Pharma, INC. | $147.24 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $145.65 | 2021-2024 | Yupelri |
| Abbvie INC. | $145.01 | 2022-2023 | |
| Ars Pharmaceuticals Operations, INC. | $138.65 | 2025 | Neffy |
| Axsome Therapeutics, INC. | $113.25 | 2025 | Sunosi |
| Viatris Specialty LLC | $108.71 | 2025 | Yupelri |
| Lilly USA, LLC | $91.84 | 2024-2025 | Ebglyss |
| Philips North America LLC | $81.10 | 2021-2025 | Vest Therapy Und |
| Leo Pharma INC. | $74.77 | 2022-2023 | Adbry |
| Organon LLC | $52.72 | 2025 | |
| Aytu Biopharma, INC. | $51.47 | 2025 | |
| Alk-Abello, INC | $48.30 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $39.90 | 2021 | |
| Hikma Pharmaceuticals USA | $29.23 | 2023-2024 | Ryaltris |
| Aimmune Therapeutics, INC. | $25.25 | 2022 | |
| Ionis Pharmaceuticals, INC. | $22.41 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $20.87 | 2024 | Ayvakit |
| Phadia US INC. | $16.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.